Webinar replay

Trends in New Oncology Treatments

Record number of new oncology treatments have been approved in recent years, bringing new treatment options to patients.  Although recent progress has deepened our understanding of the disease and has also brought on unprecedented new possibilities for personalized medicine, there are still many cancer types for which there are no, or minimally, effective therapy. Leaders in the field will discuss the latest breakthroughs in oncology research, the impact of COVID-19 on oncology drug development and insights on future trends in oncology treatment and the financial landscape for these promising new therapies.

Watch this replay to get expert insights from our panelists:
Stephanie-Oestreich
Stephanie Oestreich
PhD, Venture Partner
RA Capital, Management
Dana-Feuchtbaum
Dana Feuchtbaum
Director, Product Management, Clinico-Genomics
Flatiron Health
Elisa-Kieback-1024x1024
Elisa Kieback
CEO & Co-Founder
T-Knife
Zachary-Hornby-863x1024
Zachary Hornby
CEO, President, and Director
Boundless Bio

Resources you may be interested in

PlenarySessionsSpeakersModThumbnail (1)

Investing in Global Health Security: Overcoming Challenges in Antibiotic Development

Watch webinar replay
Neuroscience-VP_Opening-Plenary-Session_slides-1

Next Generation Advances in Neuroscience Research

Watch webinar replay
Onco VP_2021Opening Plenary Session_slides

Calculating Risk and Return in Oncology Development

Watch webinar replay

About Inova

Inova accelerates partnering for the future of medicine. Our cloud-based solutions help life science companies manage their biopharma opportunities more efficiently. They find all their partnering information in one place, track their deals and alliances easily and report on their pipeline and activities in seconds.
We have also developed strategic partnerships that make data from the 20 biggest biopharma events automatically available in Inova, providing our users with always up-to-date company and contact information. Over 150 life science companies, including 50% of the top 50 pharmaceutical companies and many midsize pharma and innovative biotechs already use Inova.